Pregnancy and Inflammatory Bowel Disease (MICI-Birth)

Inflammatory Bowel disease, including Crohn's disease and Ulcerative Colitis, are chronic diseases.

Diagnosis is most often done in women of childbearing age. IBD can have and increase the risk of intrauterine growth retardation, preterm birth… Conversely, pregnancy can have an impact on IBD activity during pregnancy. Moreover, IBD course can be influence in post-partum. The investigators will explore IBD course on 945 patients from the EPIMAD register. The investigators will cross the data on the IBD with data on pregnancy, postpartum but also breastfeeding. The principal aim of this study is to assess the number of flares during pregnancy.

Study Overview

• Status: Recruiting
• Conditions: Pregnancy; Crohn's Disease; Ulcerative Colitis; IBD

• Study Type: Observational
• Enrollment (Estimated): 945

Contacts and Locations

• Study Contact: Name: Arthur FOULON, Pr; Phone Number: 33+3 22 08 73 82; Email: foulon.arthur@chu-amiens.fr

Study Locations

• France
  • Amiens, France, 80480
    • Recruiting
    • CHU Amiens
    • Contact: Arthur Foulon, MD; Phone Number: (33)3 22 66 88 20; Email: foulon.arthur@chu-amiens.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients suffering from IBD and with at least one pregnancy.

Description

Inclusion Criteria:

• women between 18 and 50 years old
• MICI diagnosed between 1988 and 2018
• included in EPIMAD registry
• living in Somme
• having had at least one pregnancy

Exclusion Criteria:

• women who has not had pregnancy
• not included in EPIMAD register

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
IBD and pregnancy; Population-based cohort of patients suffering from IBD and with at least one pregnancy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
number of IBD flare during pregnancy	2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of flare during post-partum period		2 years
Number of pregnancy		2 years
number of children		2 years
Number of Intestinal resection	Intestinal resection due to mici during pregnancy and post-partum	2 years
Number of hospitalization	Intestinal resection and hospitalization due to mici during pregnancy and post-partum	2 years
Number of miscarriage		2 years
Number of ectopic pregnancy		2 years
Time before conception		2 years
Number of women with exposition to corticosteroid	Exposition to corticosteroid during pregnancy and post-partum	2 years
Exposition to biotherapy	Exposition to biotherapy during pregnancy and post-partum	2 years
Number and indication of cesarean section		2 years
Number of anoperineal lesions after the birth		2 years
Wexner score for continence		2 years

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire, Amiens

Study record dates

Study Major Dates

• Study Start (Actual): September 18, 2020
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026

Study Registration Dates

• First Submitted: November 17, 2025
• First Submitted That Met QC Criteria: January 22, 2026
• First Posted (Actual): January 29, 2026

Study Record Updates

• Last Update Posted (Actual): February 5, 2026
• Last Update Submitted That Met QC Criteria: February 4, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: pregnancy; IBD; Crohn's disease; Ulcerative colitis
• Additional Relevant MeSH Terms: Intestinal Diseases; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Gastroenteritis; Inflammatory Bowel Diseases; Colitis; Colitis, Ulcerative; Crohn Disease
• Other Study ID Numbers: PI2019_843_0059

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No